Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
PepGen Ltd (PEPG)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
04/01/2025: PEPG (2-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
AI Based Fundamental Rating
Above Average Performance
These Stocks/ETFs, based on Upturn Advisory, frequently surpass the market, reflecting reliable and trustworthy advice.
Analysis of Past Performance
Type Stock | Historic Profit 30.63% | Avg. Invested days 28 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  4.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 04/01/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 48.21M USD | Price to earnings Ratio - | 1Y Target Price 12.2 |
Price to earnings Ratio - | 1Y Target Price 12.2 | ||
Volume (30-day avg) 5449298 | Beta 0.98 | 52 Weeks Range 1.16 - 19.30 | Updated Date 04/1/2025 |
52 Weeks Range 1.16 - 19.30 | Updated Date 04/1/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -2.85 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -41.56% | Return on Equity (TTM) -79.26% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value -55433733 | Price to Sales(TTM) - |
Enterprise Value -55433733 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -3.11 | Shares Outstanding 32692400 | Shares Floating 10513218 |
Shares Outstanding 32692400 | Shares Floating 10513218 | ||
Percent Insiders 0.39 | Percent Institutions 102.29 |
Analyst Ratings
Rating 4.4 | Target Price 15.4 | Buy 1 | Strong Buy 3 |
Buy 1 | Strong Buy 3 | ||
Hold 1 | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
PepGen Ltd
Company Overview
History and Background
PepGen Ltd. is a biotechnology company focused on developing next-generation oligonucleotide therapeutics to treat severe neuromuscular and neurological diseases. Founded in 2018, PepGen has rapidly advanced its Enhanced Delivery Oligonucleotides (EDO) platform to address unmet needs in diseases with limited or no treatment options.
Core Business Areas
- Neuromuscular Diseases: Developing therapies for Duchenne muscular dystrophy (DMD) and other muscle-wasting conditions, focusing on exon skipping and other RNA-based approaches.
- Neurological Diseases: Exploring therapeutic applications for neurological disorders with a focus on genetic mutations that can be targeted with oligonucleotide therapies.
Leadership and Structure
James McArthur serves as President and CEO. The company has a scientific advisory board composed of experts in oligonucleotide therapeutics and neuromuscular diseases. Organizational structure includes research and development, clinical development, and business operations teams.
Top Products and Market Share
Key Offerings
- PGN-EDO51: A clinical-stage investigational therapy for Duchenne muscular dystrophy (DMD) amenable to exon 51 skipping. Phase 1 data is in progress. Market share data is not yet available as it is an investigational drug. Competitors include Sarepta Therapeutics (SRPT) with Exondys 51, Amondys 45, and Vyondys 53 and NS Pharma with Viltolarsen.
- PGN-EDODM1: An investigational therapy for Myotonic Dystrophy Type 1 (DM1). Preclinical stage. Market share data is not yet available as it is an investigational drug. Competitors include Avidity Biosciences (RNA) and Dyne Therapeutics (DYN).
Market Dynamics
Industry Overview
The oligonucleotide therapeutics market is rapidly growing, driven by advances in RNA-based therapies and targeted drug delivery. Key areas include rare genetic diseases, neuromuscular disorders, and neurological conditions. This market is characterized by high unmet medical needs and opportunities for innovative therapies.
Positioning
PepGen is positioned as a developer of next-generation oligonucleotide therapies using its EDO platform. The company focuses on enhancing drug delivery to target tissues, potentially improving efficacy and reducing off-target effects compared to existing oligonucleotide therapies.
Total Addressable Market (TAM)
The TAM for DMD and other neuromuscular disorders is estimated to be in the billions of dollars. The TAM for myotonic dystrophy is also significant. PepGen's EDO platform aims to improve the therapeutic window for these treatments. The TAM is determined based on the prevalence of the diseases being treated and costs of the treatment.
Upturn SWOT Analysis
Strengths
- Proprietary EDO platform for enhanced oligonucleotide delivery
- Focus on unmet needs in severe neuromuscular and neurological diseases
- Experienced management team with expertise in oligonucleotide therapeutics
- Strong intellectual property portfolio
Weaknesses
- Clinical-stage company with no currently approved products
- Reliance on successful clinical trial outcomes
- High R&D expenses
- Potential for competition from established pharmaceutical companies
Opportunities
- Expansion of EDO platform to additional disease targets
- Potential for partnerships and collaborations with larger pharmaceutical companies
- Positive clinical trial results leading to regulatory approvals
- Increasing market demand for targeted oligonucleotide therapies
Threats
- Clinical trial failures
- Regulatory hurdles
- Competition from existing and emerging therapies
- Patent challenges
- Financial market fluctuations
Competitors and Market Share
Key Competitors
- SRPT
- DYN
- RNA
Competitive Landscape
PepGen's EDO platform aims to provide enhanced delivery compared to competitors. It has to show clinical advantages. The company is still very early-stage compared to established players like Sarepta Therapeutics.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: Historical growth is characterized by advancing its EDO platform and progressing its lead product candidates through preclinical and clinical development.
Future Projections: Future growth depends on successful clinical trials, regulatory approvals, and commercialization of its therapies. Analyst projections depend on clinical trial outcomes and market uptake. The company is currently focused on exon-skipping therapies for DMD.
Recent Initiatives: Recent initiatives include advancing PGN-EDO51 into clinical development, expanding its EDO platform to new disease targets, and strengthening its intellectual property portfolio.
Summary
PepGen is a promising clinical-stage biotechnology company with a proprietary EDO platform that enhances oligonucleotide delivery. Its focus on unmet needs in neuromuscular and neurological diseases positions it in a high-growth market. The company's success hinges on positive clinical trial outcomes, regulatory approvals, and its ability to compete with larger pharmaceutical companies. The long-term growth is dependent on continued innovation and successful partnerships.
Similar Companies
DYN
Dyne Therapeutics Inc
DYN
Dyne Therapeutics Inc
IONS
Ionis Pharmaceuticals Inc
IONS
Ionis Pharmaceuticals Inc
RNA
Avidity Biosciences Inc
RNA
Avidity Biosciences Inc
SRPT
Sarepta Therapeutics Inc
SRPT
Sarepta Therapeutics Inc
Sources and Disclaimers
Data Sources:
- PepGen Ltd. website
- SEC filings
- Analyst reports
- Industry publications
Disclaimers:
The information provided is for informational purposes only and should not be considered financial advice. Investment decisions should be based on thorough research and consultation with a qualified financial advisor. Market share data for investigational drugs are estimates. Financial metrics are limited due to clinical-stage status.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About PepGen Ltd
Exchange NASDAQ | Headquaters Boston, MA, United States | ||
IPO Launch date 2022-05-06 | President, CEO, Treasurer, Secretary & Director Dr. James G. McArthur Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 81 | Website https://pepgen.com |
Full time employees 81 | Website https://pepgen.com | ||
PepGen Inc., a clinical-stage biotechnology company, develops oligonucleotide therapeutics for the treatment of severe neuromuscular and neurologic diseases in the United States. Its lead product candidates comprise PGN-EDO51, an EDO peptide which is Phase 2 clinical trial to treat duchenne muscular dystrophy (DMD) patients that are amenable to an exon 51-skipping approach; PGN-EDODM1, an EDO peptide-conjugated PMO, which is in Phase 2 clinical trial for the treatment of myotonic dystrophy type 1; and PGN-EDO53, which is in preclinical trial to treat duchenne muscular dystrophy. The company was founded in 2018 and is based in Boston, Massachusetts.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.